SLBT Stock Forecast: SL Science Holding Ltd. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 0 of 100 as at 1 Aug 2026 — in the weakest quartile.
SLBT stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores SL Science Holding Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (40): Smaller than most of the companies we track.
Quality (0): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
The rank is the raw material. Whether the rules would actually own SL Science Holding Ltd. — and when they’d sell — is the membership.
SLBT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SLBT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SLBT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
SL Science Holding Ltd. (SLBT) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 441.0×
- Price / book
- —
- EV / EBITDA
- −395.9×
Cheaper than 2% of US stocks
Cheaper than 99% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −35.6%
- Net margin
- −35.4%
Higher than 20% of US stocks
Higher than 12% of US stocks
- Return on equity
- −25.6%
- Return on assets
- −14.7%
- Dividend yield
- —
Higher than 29% of US stocks
Higher than 23% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
SLBT vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SLBT appears on the weeks it earns a place.
Frequently asked questions about SLBT stock
How does Ticker Nerd's model rank SLBT?
As at 1 Aug 2026, SL Science Holding Ltd. ranks 0 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (40 of 100).
What is the SLBT stock forecast for 2030?
No analyst covering SL Science Holding Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SLBT are extrapolating price history, which says nothing about the business.
What does SL Science Holding Ltd. do?
SL Science Holding Limited is a biotechnology holding company focused on developing cell and gene therapies for regenerative medicine and oncology. Its current portfolio centers on investigational immune cell technologies, including armed T-cell and gamma delta T-cell programs, alongside exosome-based products derived from non-human sources such as plants and bovine milk.
About SL Science Holding Ltd.
SL Science Holding Limited is a biotechnology holding company focused on developing cell and gene therapies for regenerative medicine and oncology. Its current portfolio centers on investigational immune cell technologies, including armed T-cell and gamma delta T-cell programs, alongside exosome-based products derived from non-human sources such as plants and bovine milk. The company operates as a platform for advancing next-generation biomedical solutions and supports research across cancer treatment and regenerative applications. SL Science Holding Limited is positioned as a science-driven company that combines therapeutic development with a broader focus on specialized biological products for medical and consumer uses.
CEO Mr. Ching-Dong Wang · Taiwan · https://www.sl-bio.com